Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYN 101 - Synthis Therapeutics

X
Drug Profile

SYN 101 - Synthis Therapeutics

Alternative Names: SYN-101

Latest Information Update: 31 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synthis Therapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Transforming growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Sep 2022 Synthis Therapeutics has patents pending for its core technology that covers ATAC platform, combination of targeting modalities, linkers and payload structures in the US and worldwide (Synthis Therapeutics website, October 2022).
  • 28 Sep 2022 Pharmacodynamics data from preclinical studies in Cancer (Combination therapy) presented at the Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2022)
  • 28 Sep 2022 Preclinical studies in Cancer in USA (Parenteral) prior to September 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top